Comparative Pharmacology
Head-to-head clinical analysis: ORENITRAM versus TREPROSTINIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORENITRAM versus TREPROSTINIL.
ORENITRAM vs TREPROSTINIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ORENITRAM (treprostinil) is a prostacyclin analog that directly vasodilates pulmonary and systemic arteries, inhibits platelet aggregation, and reduces pulmonary vascular resistance via IP receptor activation, increasing cAMP levels.
Treprostinil is a synthetic prostacyclin analogue that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and suppresses vascular smooth muscle proliferation via activation of IP receptors and subsequent increase in cAMP levels.
Initial: 0.125 mg orally twice daily; titrate as tolerated in increments of 0.125 mg twice daily every 2 weeks. Maximum dose: 1.5 mg twice daily.
Continuous subcutaneous or intravenous infusion via infusion pump. Initial rate: 1.25 ng/kg/min; if not tolerated, reduce to 0.625 ng/kg/min. Titrate in increments of 1.25 ng/kg/min per week for first 4 weeks, then 2.5 ng/kg/min per week as tolerated. Typical maintenance dose: 25-40 ng/kg/min. Duration: continuous long-term.
None Documented
None Documented
Clinical Note
moderateTreprostinil + Benzydamine
"The risk or severity of adverse effects can be increased when Treprostinil is combined with Benzydamine."
Clinical Note
moderateTreprostinil + Droxicam
"The risk or severity of adverse effects can be increased when Treprostinil is combined with Droxicam."
Clinical Note
moderateTreprostinil + Loxoprofen
"The risk or severity of adverse effects can be increased when Treprostinil is combined with Loxoprofen."
Clinical Note
moderateTreprostinil + Clonixin
Terminal elimination half-life is approximately 2-4 hours in patients with pulmonary arterial hypertension (PAH). Clinical context: Requires twice-daily dosing or continuous IV infusion to maintain therapeutic concentrations.
Terminal half-life is approximately 4 hours for intravenous administration; clinical context: requires continuous infusion due to short half-life.
Approximately 50-70% as unchanged drug and 10-15% as inactive metabolites via urine; 4-14% via feces (biliary/fecal route) as unchanged drug and metabolites. Total renal clearance accounts for ~50% of total clearance.
Primarily hepatic metabolism via CYP2C8; renal excretion of unchanged drug is approximately 4% of the dose.
Category C
Category A/B
Prostacyclin Analog
Prostacyclin Analog
"The risk or severity of adverse effects can be increased when Treprostinil is combined with Clonixin."